Scorpion Therapeutics
Boston, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $150M
Overview
A precision oncology biotech targeting 'undruggable' cancer drivers with novel small molecule therapies.
Oncology
Technology Platform
An integrated discovery platform combining chemical proteomics, structural biology, and computation to identify and drug challenging, high-value cancer targets with small molecules.
Funding History
1Total raised:$150M
Series C$150M
Opportunities
Potential for breakthrough validation and blockbuster drugs if it successfully drugs a major, previously untargetable cancer driver.
Risk Factors
High scientific and clinical risk that its novel compounds may fail to show sufficient efficacy or acceptable safety in patients.
Competitive Landscape
Competes with other well-funded biotechs pursuing 'undruggable' targets, where success depends on technological edge and clinical validation.